Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

NCT07492927 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT07492927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07492927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Lead sponsor
Xijing Hospital
Phase
Observational
Overall status
Recruiting
Start date
March 12, 2021
Completion date
June 30, 2027
Enrollment
1,700 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

clinically significant prostate cancer